Elite Pharmaceuticals, Inc. (ELTP)
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals.
The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases.
The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products.
In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection.
Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.
|IPO Date||Jul 23, 1998|
|Industry||Drug Manufacturers - Specialty & Generic|
165 Ludlow Avenue
Northvale, New Jersey 07647
|Fiscal Year||April - March|
|Nasrat Hakim||Chairman, Chief Executive Officer and Pres|
|Douglas Plassche||Executive Vice President of Operations|
|Robert Chen||Chief Financial Officer, Secretary and Treasurer|
|Dianne Will||Vice President of Investor Relations and Corporate Affairs|
|Dr. George Kenneth Smith J.D., M.B.A., Ph.D.||Vice President of Legal|
|Dr. Sophy Abraham||Head of Regulatory Affairs|
|Kirko Kirkov||Chief Commercial Officer|
Latest SEC Filings
|Nov 14, 2023||8-K||Current Report|
|Nov 14, 2023||10-Q||Quarterly Report|
|Sep 25, 2023||8-K||Current Report|
|Sep 7, 2023||8-K||Current Report|
|Aug 14, 2023||8-K||Current Report|
|Aug 14, 2023||10-Q||Quarterly Report|
|Jul 31, 2023||10-K/A||[Amend] Annual report|
|Jul 17, 2023||8-K||Current Report|
|Jun 29, 2023||8-K||Current Report|
|Jun 29, 2023||10-K||Annual Report|